Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …

Gene-expression profiling has had a considerable impact on our understanding of breast
cancer biology. During the last 15 years, 5 intrinsic molecular subtypes of breast cancer …

Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone
receptors expression and HER2 gene amplification and represents 24% of newly diagnosed …

Chemotherapy is the primary established systemic treatment for patients with triple-negative
breast cancer (TNBC) in both the early and advanced-stages of the disease. The lack of …

Purpose Cell-free DNA (cfDNA) offers the potential for minimally invasive genome-wide
profiling of tumor alterations without tumor biopsy and may be associated with patient …

Triple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular
subtypes that differentially respond to chemotherapy and targeted agents. The purpose of …

Triple-negative breast cancer (TNBC) is a long-lasting orphan disease in terms of little
therapeutic progress during the past several decades and still the standard of care remains …

Background Predicting treatment benefit and/or outcome before any therapeutic intervention
has taken place would be clinically very useful. Herein, we evaluate the ability of the intrinsic …

Gene expression profiling has had a considerable impact on our understanding of breast
cancer biology. During the last decade, 4 intrinsic molecular subtypes of breast cancer …

Importance The value of the intrinsic subtypes of breast cancer (luminal A, luminal B, human
epidermal growth factor receptor 2 [currently known as ERBB2, but referred to as HER2 in …